Enhance the dissolution rate and oral bioavailability of pranlukast by preparing nanosuspensions with high-pressure homogenizing method

References

• Weersink EJ, Postma DS, Aalbers R, de Monchy JG. (1994). Early and late asthmatic reaction after allergen challenge. Respir Med, 88:103–114.
   PubMed Web of Science ®Google Scholar
• Brocklehurst WE. (1960). The release of histamine and formation of a slow-reacting substance (SRS-A) during anaphylactic shock. J Physiol (Lond), 151:416–435.
   Google Scholar
• Kumlin M. (2000). Measurement of leukotrienes in humans. Am J Respir Crit Care Med, 161:S102–S106.
   PubMed Web of Science ®Google Scholar
• O’Byrne PM. (2000). Leukotriene bronchoconstriction induced by allergen and exercise. Am J Respir Crit Care Med, 161:68–72.
   PubMed Web of Science ®Google Scholar
• Fujimura M, Sakamoto S, Kamio Y, Matsuda T. (1993). Effect of a leukotriene antagonist, ONO-1078, on bronchial hyperresponsiveness in patients with asthma. Respir Med, 87:133–138.
   PubMed Web of Science ®Google Scholar
• Yamaguchi T, Kohrogi H, Honda I, Kawano O, Sugimoto M, Araki S et al. (1992). A novel leukotriene antagonist, ONO-1078, inhibits and reverses human bronchial contraction induced by leukotrienes C4 and D4 and antigen in vitro. Am Rev Respir Dis, 146:923–929.
   PubMed Web of Science ®Google Scholar
• Hamilton A, Faiferman I, Stober P, Watson RM, O’Byrne PM. (1998). Pranlukast, a cysteinyl leukotriene receptor antagonist, attenuates allergen-induced early- and late-phase bronchoconstriction and airway hyperresponsiveness in asthmatic subjects. J Allergy Clin Immunol, 102:177–183.
   PubMed Web of Science ®Google Scholar
• Chono S, Takeda E, Seki T, Morimoto K. (2008). Enhancement of the dissolution rate and gastrointestinal absorption of pranlukast as a model poorly water-soluble drug by grinding with gelatin. Int J Pharm, 347:71–78.
   PubMed Web of Science ®Google Scholar
• Brocks DR, Upward J, Hust R, Köester FE, Collie H, Qian Y et al. (1996). The pharmacokinetics of pranlukast in healthy young and elderly subjects. Int J Clin Pharmacol Ther, 34:375–379.
   PubMed Web of Science ®Google Scholar
• Brocks DR, Upward JW, Georgiou P, Stelman G, Doyle E, Allen E et al. (1996). The single and multiple dose pharmacokinetics of pranlukast in healthy volunteers. Eur J Clin Pharmacol, 51:303–308.
   PubMed Web of Science ®Google Scholar
• Jiraporn C, Satit P, Porntip CP, Yuichi T, Kunikazu M, Keiji Y. (2008). Formation, physical stability and in vitro antimalarial activity of dihydroartemisinin nanosuspensions obtained by co-grinding method. Drug Dev Ind Pharm, 34:314–322.
   PubMed Web of Science ®Google Scholar
• Van Eerdenbrugh B, Van den Mooter G, Augustijns P. (2008). Top-down production of drug nanocrystals: nanosuspension stabilization, miniaturization and transformation into solid products. Int J Pharm, 364:64–75.
   PubMed Web of Science ®Google Scholar
• Rabinow BE. (2004). Nanosuspensions in drug delivery. Nat Rev Drug Discov, 3:785–796.
   PubMed Web of Science ®Google Scholar
• Pathak P, Meziam MJ, Desai T, Sun YP. (2006). Formation and stabilization of ibuprofen nanoparticles in supercritical fluid processing. J Supercrit Fluids, 37:279–286.
   Web of Science ®Google Scholar
• Reverchon E. (1999). Supercritical antisolvent precipitation of micro- and nano-particles. J Supercrit Fluids, 15:1–21.
   Web of Science ®Google Scholar
• Xia D, Quan P, Piao H, Piao H, Sun S, Yin Y et al. (2010). Preparation of stable nitrendipine nanosuspensions using the precipitation-ultrasonication method for enhancement of dissolution and oral bioavailability. Eur J Pharm Sci, 40:325–334.
   PubMed Web of Science ®Google Scholar
• Nagarwal RC, Kumar R, Dhanawat M, Das N, Pandit JK. (2011). Nanocrystal technology in the delivery of poorly soluble drugs: an overview. Curr Drug Deliv, 8:398–406.
   PubMed Web of Science ®Google Scholar
• Kakran M, Shegokar R, Sahoo NG, Al Shaal L, Li L, Müller RH. (2012). Fabrication of quercetin nanocrystals: Comparison of different methods. Eur J Pharm Biopharm, 80:113–121.
   PubMed Web of Science ®Google Scholar
• Jacobs C, Kayser O, Müller RH. (2000). Nanosuspensions as a new approach for the formulation for the poorly soluble drug tarazepide. Int J Pharm, 196:161–164.
   PubMed Web of Science ®Google Scholar
• Mitri K, Shegokar R, Gohla S, Anselmi C, Müller RH. (2011). Lutein nanocrystals as antioxidant formulation for oral and dermal delivery. Int J Pharm, 420:141–146.
   PubMed Web of Science ®Google Scholar
• Kocbek P, Baumgartner S, Kristl J. (2006). Preparation and evaluation of nanosuspensions for enhancing the dissolution of poorly soluble drugs. Int J Pharm, 312:179–186.
   PubMed Web of Science ®Google Scholar
• Sun W, Mao S, Shi Y, Li LC, Fang L. (2011). Nanonization of itraconazole by high pressure homogenization: stabilizer optimization and effect of particle size on oral absorption. J Pharm Sci, 100:3365–3373.
   PubMed Web of Science ®Google Scholar
• Gao L, Zhang D, Chen M, Zheng T, Wang S. (2007). Preparation and characterization of an oridonin nanosuspension for solubility and dissolution velocity enhancement. Drug Dev Ind Pharm, 33:1332–1339.
   PubMed Web of Science ®Google Scholar
• Mauludin R, Müller RH, Keck CM. (2009). Kinetic solubility and dissolution velocity of rutin nanocrystals. Eur J Pharm Sci, 36:502–510.
   PubMed Web of Science ®Google Scholar
• Kommuru TR, Gurley B, Khan MA, Reddy IK. (2001). Self-emulsifying drug delivery systems (SEDDS) of coenzyme Q10: formulation development and bioavailability assessment. Int J Pharm, 212:233–246.
   PubMed Web of Science ®Google Scholar
• Keck CM, Müller RH. (2006). Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. Eur J Pharm Biopharm, 62:3–16.
   PubMed Web of Science ®Google Scholar
• Voorhees PW. (1985). The theory of Ostwald ripening. J Stat Phys, 38:231–252.
   Web of Science ®Google Scholar
• Dolenc A, Govedarica B, Dreu R, Kocbek P, Srcic S, Kristl J. (2010). Nanosized particles of orlistat with enhanced in vitro dissolution rate and lipase inhibition. Int J Pharm, 396:149–155.
   PubMed Web of Science ®Google Scholar
• Sigfridsson K, Lundqvist AJ, Strimfors M. (2009). Particle size reduction for improvement of oral absorption of the poorly soluble drug UG558 in rats during early development. Drug Dev Ind Pharm, 35:1479–1486.
   PubMed Web of Science ®Google Scholar
• Raghavan SL, Trividic A, Davis AF, Hadgraft J. (2001). Crystallization of hydrocortisone acetate: influence of polymers. Int J Pharm, 212:213–221.
   PubMed Web of Science ®Google Scholar
• Zimmermann A, Millqvist-Fureby A, Elema MR, Hansen T, Müllertz A, Hovgaard L. (2009). Adsorption of pharmaceutical excipients onto microcrystals of siramesine hydrochloride: effects on physicochemical properties. Eur J Pharm Biopharm, 71:109–116.
   PubMed Web of Science ®Google Scholar
• Sigfridsson K, Lundqvist A, Strimfors M. (2011). Co-administration of a nanosuspension of a poorly soluble basic compound and a solution of a proton pump inhibitor–the importance of gastrointestinal pH and solubility for the in vivo exposure. Drug Dev Ind Pharm, 37:1036–1042.
   PubMed Web of Science ®Google Scholar
• Douroumis D, Fahr A. (2007). Stable carbamazepine colloidal systems using the cosolvent technique. Eur J Pharm Sci, 30:367–374.
   PubMed Web of Science ®Google Scholar
• Taylor LS, Zografi G. (1997). Spectroscopic characterization of interactions between PVP and indomethacin in amorphous molecular dispersions. Pharm Res, 14:1691–1698.
   PubMed Web of Science ®Google Scholar
• Shatalova OV, Krivandin AV, Aksenova NA, Solov’eva AB. (2008). Structure of Pluronic F-127 and its tetraphenylporphyrin complexes: X-ray diffraction study. Polym Sci Ser A, 50:417–421.
   Web of Science ®Google Scholar
• Storm G, Belliot SO, Daemen T, Lasic DD. (1995). Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system. Adv Drug Deliv Rev, 17:31–48.
   Web of Science ®Google Scholar
• Bhakay A, Merwade M, Bilgili E, Dave RN. (2011). Novel aspects of wet milling for the production of microsuspensions and nanosuspensions of poorly water-soluble drugs. Drug Dev Ind Pharm, 37:963–976.
   PubMed Web of Science ®Google Scholar
• Li JT, Caldwell KD. (1996). Plasma protein interactions with Pluronic(TM)-treated colloids. Colloids Surf, B-Biointerfaces, 7:9–22.
   Web of Science ®Google Scholar
• Moghimi SM, Hunter AC. (2000). Poloxamers and poloxamines in nanoparticle engineering and experimental medicine. Trends Biotechnol, 18:412–420.
   PubMed Web of Science ®Google Scholar
• Zhang ZL, Le Y, Wang JX, Chen JF. (2011). Preparation of stable micron-sized crystalline irbesartan particles for the enhancement of dissolution rate. Drug Dev Ind Pharm, 37:1357–1364.
   PubMed Web of Science ®Google Scholar
• Sigfridsson K, Nordmark A, Theilig S, Lindahl A. (2011). A formulation comparison between micro- and nanosuspensions: the importance of particle size for absorption of a model compound, following repeated oral administration to rats during early development. Drug Dev Ind Pharm, 37:185–192.
   PubMed Web of Science ®Google Scholar